GGrantIndex
← Leaderboards

Paul K Drain

University Of Washington

Google Scholar ↗PubMed ↗ORCID ↗
$9,543,445
Attributed
$16,394,271
Total exposure
9
Grants
8
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $2.7M · FY2014–25
$5M$3.8M$2.5M$1.3M$0
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$16,394,271 · 9

By mechanism

R01$14,190,666 · 4
R21$1,130,319 · 3
K23$927,815 · 1
R03$145,471 · 1

Top collaborators

Most similar at University Of Washington

Same institution · by research overlap

Others in their field

Top investigators on “Antiretroviral Therapy”

Research focus

Antiretroviral TherapyClinicTransmission ProcessSamplingUrinePreventBaseLaboratoriesTenofovirCaringAdultPoint Of CareResourcesTrainingImplementation ScienceInnovationMonitorSpecimenAcquired Immunodeficiency SyndromeCostCost EffectivenessMortalitySouth AfricaCost Effective

Grant awards (32)

A novel REverSe Transcriptase Chain Termination (RESTRICT) assay for near-patient, objective monitoring of long-term PrEP adherence$747,346
R01 · FY2025 · AI · contact PI
A novel REverSe Transcriptase Chain Termination (RESTRICT) assay for near-patient, objective monitoring of long-term PrEP adherence$771,421
R01 · FY2024 · AI · contact PI
Improving Native American Health Through Community-based Screening and Diagnostic Testing for Tuberculosis$398,580
R21 · FY2024 · NR · contact PI
Simplifying HIV Treatment and Monitoring (STREAM2): Point-of-Care Urine Tenofovir Adherence and Viral Load Testing to Improve HIV Outcomes in South Africa$371,692
R01 · FY2024 · AI · contact PI
Drug Resistance Genotypic and Phenotypic Correlates of Efavirenz and Dolutegravir based Treatment Outcomes across Non-B HIV-1 subtypes$780,602
R01 · FY2023 · AI
A novel REverSe Transcriptase Chain Termination (RESTRICT) assay for near-patient, objective monitoring of long-term PrEP adherence$771,422
R01 · FY2023 · AI · contact PI
Simplifying HIV Treatment and Monitoring (STREAM2): Point-of-Care Urine Tenofovir Adherence and Viral Load Testing to Improve HIV Outcomes in South Africa$348,046
R01 · FY2023 · AI · contact PI
Drug Resistance Genotypic and Phenotypic Correlates of Efavirenz and Dolutegravir based Treatment Outcomes across Non-B HIV-1 subtypes$1,219,140
R01 · FY2022 · AI
A novel REverSe Transcriptase Chain Termination (RESTRICT) assay for near-patient, objective monitoring of long-term PrEP adherence$770,460
R01 · FY2022 · AI · contact PI
Simplifying HIV Treatment and Monitoring (STREAM2): Point-of-Care Urine Tenofovir Adherence and Viral Load Testing to Improve HIV Outcomes in South Africa$689,168
R01 · FY2022 · AI · contact PI
Drug Resistance Genotypic and Phenotypic Correlates of Efavirenz and Dolutegravir based Treatment Outcomes across Non-B HIV-1 subtypes$819,182
R01 · FY2021 · AI
A novel REverSe Transcriptase Chain Termination (RESTRICT) assay for near-patient, objective monitoring of long-term PrEP adherence$767,819
R01 · FY2021 · AI · contact PI
Simplifying HIV Treatment and Monitoring (STREAM2): Point-of-Care Urine Tenofovir Adherence and Viral Load Testing to Improve HIV Outcomes in South Africa$679,044
R01 · FY2021 · AI · contact PI
Drug Resistance Genotypic and Phenotypic Correlates of Efavirenz and Dolutegravir based Treatment Outcomes across Non-B HIV-1 subtypes$834,531
R01 · FY2020 · AI
A Rapid Point-of-Care Test to Improve ART and PrEP Adherence$765,546
R01 · FY2020 · AI · contact PI
Simplifying HIV Treatment and Monitoring (STREAM2): Point-of-Care Urine Tenofovir Adherence and Viral Load Testing to Improve HIV Outcomes in South Africa$673,184
R01 · FY2020 · AI · contact PI
Advancing point-of-care diagnostics for integrated HIV and TB care in South Africa$72,660
R03 · FY2020 · AI · contact PI
Drug Resistance Genotypic and Phenotypic Correlates of Efavirenz and Dolutegravir based Treatment Outcomes across Non-B HIV-1 subtypes$900,704
R01 · FY2019 · AI
A Rapid Point-of-Care Test to Improve ART and PrEP Adherence$777,019
R01 · FY2019 · AI · contact PI
Simplifying HIV Treatment and Monitoring (STREAM2): Point-of-Care Urine Tenofovir Adherence and Viral Load Testing to Improve HIV Outcomes in South Africa$703,639
R01 · FY2019 · AI · contact PI
Advancing point-of-care diagnostics for integrated HIV and TB care in South Africa$72,811
R03 · FY2019 · AI · contact PI
A Rapid Point-of-Care Test to Improve ART and PrEP Adherence$800,701
R01 · FY2018 · AI · contact PI
Clinic-based Screening to Prevent HIV-associated Cryptococcal Mortality$189,362
K23 · FY2018 · AI · contact PI
A Point-of-Care Assay to Measure Tenofovir for Monitoring PrEP and ART Adherence$202,948
R21 · FY2017 · AI · contact PI
Clinic-based Screening to Prevent HIV-associated Cryptococcal Mortality$189,362
K23 · FY2017 · AI · contact PI
Point-of-care viral load testing to enable task shifting for chronic HIV care$180,600
R21 · FY2017 · AI · contact PI
A Point-of-Care Assay to Measure Tenofovir for Monitoring PrEP and ART Adherence$192,591
R21 · FY2016 · AI · contact PI
Clinic-based Screening to Prevent HIV-associated Cryptococcal Mortality$175,149
K23 · FY2016 · AI · contact PI
Point-of-care viral load testing to enable task shifting for chronic HIV care$155,600
R21 · FY2016 · AI · contact PI
Clinic-based Screening to Prevent HIV-associated Cryptococcal Mortality$149,202
K23 · FY2015 · AI · contact PI
Clinic-based Screening to Prevent HIV-associated Cryptococcal Mortality$36,548
K23 · FY2015 · AI · contact PI
Clinic-based Screening to Prevent HIV-associated Cryptococcal Mortality$188,192
K23 · FY2014 · AI · contact PI